MYO10

Across TCGA pan-cancer cohorts, MYO10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MYO10 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYO10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYO10 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where MYO10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.708	0.933	.002	17	view →
LUAD	DFS	Quartile	All	0.550	1.000	.008	15	view →
UCEC	DFS	Median	All	1.000	0.936	.021	8	view →
LSCC	DFS	Tertile	All	0.641	0.848	.025	8	view →
GBM	DFS	Tertile	All	0.508	0.284	.012	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.517	1.000	.036	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MYO10–PDAC (OS)

Open the PDAC breakdown →